Next-IO™ Anti-4-1BBL Therapeutic Fusion Protein Program

This program aims to develop anti-4-1BBL therapeutic fusion protein for immuno-oncology. The 4-1BBL agonistic antibodies, used alone or in combination with other anticancer drugs, have shown various therapeutic efficacies. However, presently, several ongoing clinical trials to evaluate the efficacy of agonistic 4-1BBL antibodies have reported significant hepatotoxicity and other complications in preclinical and clinical studies. In marked contrast, the latest data have dominated that 4-1BB ligand chimeric fusion protein shows robust T-effector responses with therapeutic efficacy in various preclinical tumor models, highlighting a clear rationale for 4-1BBL-FP-based cancer immunotherapy. For more: Next-IO™ Anti-4-1BBL Therapeutic Fusion Protein Program

888